Baxter International Inc.

Baxter Healthcare Sa

Dyax Corporation

Stichting Sanquin Bloedvoorziening

Baxter Health S.a.

Baxalta Gmbh

Manfred Rieger

Friedrich Scheiflinger

Barbara Plaimauer

Rene Hoet

Randolf Kerschbaumer

Geert Mudde

Koenraad Mertens

Michael Thiele

Arend N Bovenschen

Jan Voorberg

Juergen Muellberg

Arend Niels Bovenschen

C Geert Mudde

Jürgen Muellberg

The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.

Anti MIF antibodies

The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.

Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII

This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease ('anti-vWF-cp') antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.

Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies

Growing community of inventors

Korneuburg, Austria

Manfred Rieger